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only small variation of the excessive cost distribution can be
explained by quality.
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OBJECTIVE: To evaluate the impact of guidelines for treatment
and prophylaxis of VTE on appropriateness of anticoagulant
therapy, JCAHO performance measures, adverse drug outcomes,
and total cost of therapy. METHODS: We conducted a multi-
hospital ‘pre-post’ guideline intervention study. Guidelines for
VTE treatment and prophylaxis were developed and imple-
mented in the participating hospitals. Retrospective chart review
was used to collect patient data during the pre and post periods.
RESULTS: The number of participating hospitals and total
patient cases submitted by the hospitals were 23 and 617, respec-
tively in the pre-guideline (PRG) phase and 13 and 338, respec-
tively in the post-guideline phase (POG). The appropriateness of
prescribing (as measured by the dose, duration, and the type of
anticoagulant used) increased by 7% (PRG 77%, POG 84%).
JCAHO performance measures for 1) percentage of VTE patients
receiving education; 2) percentage of patients with reduced
LMWH dosage in compromised renal failure; 3) percentage of
patients with normal INR; 4) percentage of patients with objec-
tive conﬁrmation of clinically suspected VTE; 5) percentage of
unfractionated heparin (UFH) managed by nomogram/protocol;
and 6) percentage of patients with anticoagulation overlap of
parenteral and warfarin therapy, increased by 20%,17%, 13%,
9%, 6%, and 1%, respectively. JCAHO measures for 1) VTE
treatment for discharged patients with active cancer, and 2) plate-
let count monitoring for patients with VTE receiving UFH,
decreased by 2% and 11%, respectively. The proportion of
patients experiencing at least one anticoagulant related adverse
drug outcome decreased by 0.5% and rates of major bleeding
decreased by 1% in POG. On average, the total cost of therapy
(cost of major/minor bleeding, DVT, PE and drugs costs)
decreased by $105 per patient in POG.
CONCLUSION: Implementation of VTE treatment and pro-
phylaxis guidelines improved appropriateness of anticoagulant
therapy in the participating hospitals resulting in improved out-
comes, reduced costs, and improved quality performance.
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OBJECTIVE: Numerous clinical outcomes trials have demon-
strated the beneﬁts of achieving glycemic goals in patients with
type 2 diabetes (T2D). In controlled clinical trials, the incretin
mimetic exenatide improved glycemic control in patients with
T2D; 34% to 46%of patients achieved A1C7%andmeanA1C
change from baseline was -0.8% to -0.9% (baseline A1Cs: 8.2%
to 8.7%). To investigate the effects of exenatide in clinical practice,
this retrospective cohort study used a large, US commercial health
plan claims database to describe baseline characteristics, comor-
bidities, concomitant therapies, and clinical effectiveness in
patients initiated on exenatide. METHODS: A total of 4936
patients were identiﬁed having a new prescription claim for
exenatide between May 1, 2005 and June 30, 2006 (ﬁrst
claim = index date), with 12 months of pre- and post-index
eligibility, and 18 years old. RESULTS: Mean (SD) age was
53.7  10.2 years (11.7% 65 y; 52% female). The 12-month
mean (SE) medication possession ratio (MPR = days of supply/
365 days) in patients with >1 prescription claim was 66  30%.
Most patients analyzed (94%)were treated with at least one other
antidiabetic medication at initiation (100 d pre-index to 15 d
post-index); 25% with one drug, 35% with two drugs, and 34%
with3 drugs. The mean number of antidiabetic drugs (including
exenatide) per patient was similar at initiation (3.08) and post-
index (3.05). Clinical effectiveness was measured in all patients
with an A1C >7.0% at baseline (100 d pre-index) and having
both baseline and post-index (60–365 d) A1C data available
(n = 201; mean baseline A1C = 8.9  1.5%). In this cohort, 31%
achieved A1C 7% in the post-index period and mean A1C
change from baseline was -0.8%. CONCLUSION: The mean
change in A1C and percentage of patients achieving A1C7% in
this real-world analysis mirrored results of controlled clinical
trials. Furthermore, glycemic improvement was achieved without
a further increase in concomitant antidiabetic drugs.
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OBJECTIVE: To study dosing frequency of metformin in relation
to HbA1c-goal attainment in daily practice. METHODS: Data
for this nested case-control study were obtained from the
PHARMO Record Linkage System, including among others
linked drug-dispensing and clinical-laboratory records of
approximately three million individuals in deﬁned areas of The
Netherlands. The study cohort included new users of oral
glucose-lowering drugs (OGLD) between 1999–2005, with a
baseline HbA1c 7% and consecutive HbA1c-measurements
within 18 months. Cases attained HbA1c-goal (HbA1c <7%)
within 18 months. Controls did not attain HbA1c-goal. Compli-
ant cases and controls on metformin monotherapy were included
in the analyses. Dosing frequency was dichotomized into once-
daily and twice-daily or more. In the multivariate analysis we
considered OGLD-dose, baseline HbA1c, prescriber and number
of HbA1c-measurements. RESULTS: The study cohort included
3107 new OGLD-users. The analyses included 753 cases and 477
controls using metformin. Dosing twice-daily or more was asso-
ciated with a 71% higher probability of attaining goal (OR 1.71
(95%CI 1.31–2.24)) compared to once-daily dosing, after adjust-
ment for baseline HbA1c and prescriber. We could not distin-
guish between the effect of dose and dosing frequency as these
were closely related. Statistical testing in the analyses stratiﬁed by
dose was prohibited by small numbers. CONCLUSION: About
40% of compliant metformin users were not at goal because of
dosing problems. A strong correlation between total daily dose
and dosing frequency did, however, not permit to identify one of
these dosing items as most important attribute.
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